Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

Inclusion Criteria: * Adult, at least 19 years of age. * Hyperlipidemia patient of LDL-C≤250 mg/dl and TG ≤400 mg/dl * Patients requiring anti-dyslipidemia drug therapy \[based on the NCEP ATP III(2002)\] * Drug compliance during Run-in period ≥70% * Patients must willing to the study and signed an informed consent Exclusion Criteria: * Patients with myopathy included rhabdomyolysis or CPK level≥2xULN * Patients with acute arterial disease * Patients with renal dysfunction or Serum creatinine level ≥2x ULN * Patients with liver dysfunction or ALT, AST level \> 2xULN * Patients with medical history within 6 months prior to screening visit (Heart failure, uncontrolled arrhythmia, drug and alcohol abuse history, gastrointestinal disease or surgery, anticoagulation disease) * Patient with uncontrolled disease (diabetes mellitus as HbA1c level of \> 9.0%, hypertension as SBP≥180mmHg or DBP≥110mmHg, hypothyroidism as TSH≥1.5xULN) * Patients who have a history or presence of active malignancy within 5 years * Patients with difficulty of stop taking lipid-lowering agents during run-in period. * Patients who have taken another investigational drug within 4 weeks prior to screening visit.